Real world evidence: Lessons learned from an FDA pilot show the limits of emulating RCTs
Only about half of a select group of clinical trials could be well-emulated with available real world evidence, according to the newly discussed results of an FDA pilot program.
The FDA-funded program, known as RCT-DUPLICATE, helped researchers from the Brigham and Women’s Hospital in Boston try to evaluate whether randomized controlled trials can be duplicated with RWE across a range of therapeutic areas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.